Is Your Paper Ready for JAMA? Journal of the American Medical Association Checklist

JAMA (Journal of the American Medical Association) states that it accepts 10% of its submissions (4% of research manuscripts), publishes no desk-rejection rate, and sets firm word limits for every article type. Its impact factor sits around 55.0, making it one of the most cited general medical journals in the world.

For journal background beyond this readiness checklist, see the JAMA Journal of the American Medical Association journal hub.

JAMA's article types aren't suggestions. They're rigid categories with hard word limits, and editors won't reformat your paper for you. Submitting a 4,500-word manuscript as an Original Investigation (3,000-word cap) is asking for trouble. Here's what you're working with:

This is JAMA's flagship format. It's where the large RCTs, major cohort studies, and practice-changing observational research live. You get 3,000 words of text (excluding abstract, tables, figures, acknowledgments, references, and online-only material) and up to 5 tables/figures combined; JAMA's instructions give no reference limit for an Original Investigation (50-75 references apply to clinical trials and meta-analyses). The structured abstract of up to 350 words has its own strict format with headings like Importance, Objective, Design, Setting, Participants, Exposures or Interventions, Main Outcomes and Measures, Results, and Conclusions and Relevance.

Three thousand words isn't much. If you're used to writing for specialty journals that give you 5,000-6,000 words, you'll need to cut aggressively. Treat the limit as a feature, not a constraint. If you can't tell the story in 3,000 words, the story probably isn't focused enough.

This is JAMA's most underused format, and honestly, it's where many authors should start. Research Letters are concise (800 words of text, 10 references, up to 2 small tables or figures). They don't include an abstract or Key Points. They're meant for concise, practice-relevant findings that don't need the full Original Investigation treatment.

Here's what most people don't realize: a Research Letter in JAMA still carries the JAMA name and the JAMA JIF. For early-career researchers or for preliminary findings from a larger study, this format can be strategic.

Viewpoints run up to 1,200 words of text (or 1,000 words with 1 small table or figure) with no abstract and no more than 7 references. They're opinion pieces, but they aren't casual. JAMA Viewpoints need to make a specific argument about clinical practice, health policy, or medical education. They shouldn't read like editorials that could appear in any newspaper. The best ones propose something concrete: a policy change, a shift in clinical thinking, a reinterpretation of existing evidence.

JAMA describes Viewpoints as short opinion-based articles that generally are not linked to a specific article. The bar is high. You'll need genuine expertise and a genuinely fresh perspective.

JAMA's Systematic Reviews and Narrative Reviews each require a presubmission inquiry to the editorial office before you submit, so don't send an unsolicited full review manuscript. If you've got a review manuscript, start with that inquiry or consider a JAMA Network specialty journal.

These manuscripts describe an important issue in clinical medicine, public health, health policy, or medical research in a scholarly, thorough, well-referenced, systematic, and evidence-based manner. The limit is 3,000 words of text, no more than 4 tables and/or figures and no more than 50 references; a structured abstract and a presubmission inquiry are required. If your paper is important but isn't a traditional study, Special Communication might be the right fit.

I can't stress this enough. JAMA sets a firm word limit for each article type, and the limits are not suggestions. This isn't PLOS ONE, where you can write 8,000 words and nobody blinks.

Here's a practical breakdown:

If your Original Investigation draft is at 4,200 words, don't submit and hope they won't notice. They will. Cut it to 3,000 or consider whether some of the content belongs in a supplement.

JAMA does not publish a desk-rejection rate. It says all submitted manuscripts are reviewed initially by one of the editors, that manuscripts with insufficient priority for publication are rejected promptly, and that others go to expert consultants for peer review; overall it accepts 10% of submissions (4% of research manuscripts). In our experience, the editors apply a consistent set of filters.

Filter 1: Article type and formatting compliance. Wrong article type, exceeded word limit, missing structured abstract headings, incomplete author disclosures. These are instant rejections that have nothing to do with your science.

Filter 2: Scope and audience match. JAMA's readers are generalist physicians. Research that matters only to subspecialists gets redirected to JAMA Network specialty journals. Work that's primarily relevant to non-US health systems may be a better fit for The Lancet or BMJ.

Filter 3: Clinical significance at scale. JAMA wants studies that could change practice for a large number of patients or affect health policy in a measurable way. A pilot study with 30 patients, no matter how well designed, won't pass this filter unless the preliminary findings are genuinely surprising.

Filter 4: Methodological red flags. The desk editors are trained to spot issues fast. Observational studies without pre-registration, clinical trials with surrogate endpoints when hard endpoints were feasible, systematic reviews that don't follow PRISMA, these trigger immediate skepticism.

If you've survived all four filters, congratulations. You're past the first editorial screen.

Here's where JAMA asks for more than many authors expect. Its instructions tell authors to follow the matching EQUATOR reporting guideline, to describe the statistical tests in a Statistical Analysis subsection at the end of the Methods, and to submit a Study Protocol with a Statistical Analysis Plan for all randomized and nonrandomized clinical trials. JAMA does not publish how its statistical review works, so write as though your analytical choices, sample size justification, and any deviation from your pre-specified analysis plan will be questioned.

What to check:

• Reporting guideline compliance. CONSORT for RCTs, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic accuracy studies. If your CONSORT checklist has items marked "not applicable" that clearly are applicable, expect to be asked about it.

• Pre-registration consistency. JAMA Network requires registration of all clinical trials in a public trials registry acceptable to the ICMJE, so expect your registered primary endpoint to be compared with what you actually report. Endpoint switching without transparent disclosure is a rejection risk.

• Multiplicity corrections. Multiple comparisons without adjustment, subgroup analyses that weren't pre-specified, and secondary analyses presented as primary findings, these are all common reasons for statistical rejection.

• Effect size reporting. P-values alone won't cut it. JAMA expects confidence intervals, and ideally absolute risk differences alongside relative measures. A hazard ratio of 0.75 means nothing without context about baseline risk.

JAMA does not publish whether statistical review runs in parallel with clinical peer review or how long it adds, so plan for statistical questions to arrive alongside clinical ones.

JAMA's submission portal has several requirements that trip up first-time submitters:

Cover letter specifics. JAMA's instructions ask for a cover letter with the corresponding author's complete contact information (affiliation, postal address, email address, and telephone number) and a statement of whether the authors have published, posted, or submitted any related papers from the same study. It is also sensible to state which article type you're submitting and to confirm that the work hasn't been published or submitted elsewhere. The instructions say nothing about suggesting reviewers.

Authorship Form and disclosures. All authors (the corresponding author and each coauthor) must complete and submit an electronic Authorship Form, which includes the Disclosure of Potential Conflicts of Interest section. Not just the corresponding author. Every single one. For a paper with 15 authors, this is logistically painful.

Data sharing statement. For all reports of research, JAMA requires a Data Sharing Statement indicating whether data will or will not be shared. Specific questions are included in the manuscript submission system: which data, when, where, and how the data will be available, which analyses are permitted, and any restrictions on use. Authors can also explain why data may not be shared.

Author contributions. JAMA requires authors to identify their specific contributions to the work; for reports of original data, these are published in the Acknowledgment section. JAMA's instructions do not mention CRediT.

JAMA doesn't publish formal submission windows, but timing still matters if your findings are time-sensitive.

Also worth knowing: JAMA has a rapid track, JAMA Express, with expedited peer review and online publication within 4 weeks of submission for late-breaking research to be presented at major scientific meetings and for findings of major clinical or public health importance that are time-sensitive. For JAMA-EXPRESS, authors send the manuscript file and a request letter to the address given in JAMA's instructions.

A JAMA manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

Not every good paper belongs in JAMA, and that's fine. The JAMA Network has 13 journals, and authors can preselect referral of a paper JAMA does not accept, with reviewers' comments if available, to a JAMA Network journal. JAMA Network Open has become an especially strong destination for rigorous studies that don't quite reach the flagship's significance threshold.

Before submitting, honestly assess whether your work speaks to general medicine or to a specialty audience. If it's really a cardiology paper, JAMA Cardiology might be a better initial target than the flagship. You won't lose prestige, and you'll save months.

A JAMA article type, formatting, and statistical reporting check can help you identify whether your article type choice, formatting, and statistical reporting align with JAMA's specific requirements before you enter the queue.

For manuscripts targeting JAMA (Journal of the American Medical Association), five patterns generate the most consistent desk rejections worth knowing before submission.

The observational association without clinical meaningfulness (~35%). In our experience, roughly 35% of desk rejections we see from JAMA-bound manuscripts involve studies that identify a statistically significant association but fail to place it in clinical context. JAMA's author guidelines ask for absolute numbers and/or rates alongside any ratio measure and say P values should never be presented alone. Editors consistently reject papers where the association is real but the clinical relevance of the effect size is never established.

The surrogate endpoint trial (~25%). In our experience, roughly 25% of rejected clinical trial manuscripts fail JAMA's surrogate endpoint standard. Papers claiming benefit on biomarkers without a validated connection to mortality or quality of life are treated as incomplete by JAMA editors. Editors consistently apply this standard rigorously; a statistically significant improvement in a surrogate does not satisfy the journal's evidence threshold unless the surrogate has been validated as a predictor of patient-relevant outcomes.

The meta-analysis that confirms what is already known (~20%). In our experience, roughly 20% of rejected systematic reviews and meta-analyses are declined because they do not resolve genuine clinical uncertainty. JAMA expects meta-analyses to answer a question that practicing clinicians are actually uncertain about; papers that synthesize a literature where the answer was already reasonably clear face desk rejection regardless of methodological quality. Editors consistently ask whether the synthesis changes anything a clinician would do.

The diagnostic accuracy paper without clinical impact assessment (~15%). In our experience, roughly 15% of rejected diagnostic papers fail because sensitivity and specificity are reported without demonstrating whether the test result changes treatment decisions. JAMA treats papers reporting test performance metrics without clinical impact assessment as incomplete for its standards. Editors consistently expect authors to show that the diagnostic information affects management, not just that the test performs well statistically.

The health policy paper without actionable recommendations (~10%). In our experience, roughly 10% of rejected health policy and economics submissions are declined because findings are descriptive without connecting to specific, actionable policy recommendations. JAMA publishes health policy research oriented toward changing clinical practice or health systems. Editors consistently screen for whether the analysis can drive a real decision, not whether it documents a problem.

SciRev community data for JAMA (Journal of the American Medical Association) offers an additional, unofficial benchmark for review timelines.

Before submitting to JAMA, a JAMA submission readiness check identifies whether your study design, effect size framing, and endpoint selection meet JAMA's editorial bar before you commit to the submission.

Use these adjacent readiness checks when the target journal is still being chosen:

• Is My Paper Ready for JACS

• Is My Paper Ready for Science Advances

• Is My Paper Ready for Lancet

• Is My Paper Ready for Neuron

• Is My Paper Ready for Nature Methods

• Is My Paper Ready for Molecules

• Is My Paper Ready for IEEE Access

• Is My Paper Ready for Physical Review D

• Is My Paper Ready for Physical Review Letters

• Is My Paper Ready for Molecular Systems Biology

This page was built from JAMA's official Instructions for Authors, the JAMA journal homepage, JAMA Network article-type guidance, Clarivate context, and Manusights pre-submission review patterns from medical manuscripts targeting JAMA, JAMA Network journals, The Lancet, BMJ, NEJM, and major specialty journals.

Source limitations: we did not submit a live test manuscript to the private JAMA portal. Use JAMA's official instructions for final upload mechanics, current article-type labels, disclosure forms, and portal fields. Use this page for the readiness decision before you spend that submission.

Source limitations: This Is Your Paper Ready for JAMA? Journal of the American Medical Association Checklist page combines official guidance where available, public publisher or product materials, and our review work for JAMA (Journal of the American Medical Association); it is an independent readiness screen, not official guidance from the journal, publisher, or service.

In our work, we observe that authors use JAMA (Journal of the American Medical Association) comparisons to decide whether they need writing support, editing, or submission-readiness judgment; this page keeps those jobs separate instead of treating every tool as a substitute.

Ready and well-matched are two different questions. See where JAMA lands among the venues that fit my abstract.